Dr. Wang on Acalabrutinib Activity in Mantle Cell Lymphoma

Michael Wang, MD
Published: Monday, Dec 11, 2017



Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses results from the phase II ACE-LY-004 trial, which explored the BTK inhibitor acalabrutinib (Calquence) in patients with refractory mantle cell lymphoma (MCL).

The international trial included 40 hospitals across 10 countries, in which 124 patients were treated with acalabrutinib, which showcased promising activity in those with refractory MCL, Wang explains. This agent brings upon a new era for patients who may have typically received chemotherapy. Additionally, the drug can be administered orally. The agent is also associated with better efficacy than chemotherapy and an improved safety profile, he adds.

Wang says acalabrutinib will also be an improvement for patients' quality of life.


Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses results from the phase II ACE-LY-004 trial, which explored the BTK inhibitor acalabrutinib (Calquence) in patients with refractory mantle cell lymphoma (MCL).

The international trial included 40 hospitals across 10 countries, in which 124 patients were treated with acalabrutinib, which showcased promising activity in those with refractory MCL, Wang explains. This agent brings upon a new era for patients who may have typically received chemotherapy. Additionally, the drug can be administered orally. The agent is also associated with better efficacy than chemotherapy and an improved safety profile, he adds.

Wang says acalabrutinib will also be an improvement for patients' quality of life.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x